Starpharma Holdings Limited, a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications, today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.
This approval means that VivaGel® and the VivaGel® coated condom are now covered by granted patents in all major markets including Europe, the US and Japan.
Last month Starpharma announced a full licence agreement with SSL International plc (LSE:SSL) in relation to the VivaGel® coated condom, with estimated receipts in excess of A$100m comprising royalties, milestone payments and development support. In addition Starpharma is continuing to develop VivaGel® as a stand-alone product for use by women to protect themselves from HIV and HSV-2 (genital herpes). The development for these two indications has significant NIH support.